An international survey of healthcare providers’ knowledge of cardiac complications of cancer treatments
Jiming Peng(University of Ottawa), Susan Dent(Government of the United States of America), Moira Rushton(University of Ottawa), Christine Brezden‐Masley(Mount Sinai Hospital), Christopher Johnson(Ottawa Hospital), Ian D. Graham(University of Ottawa), Miliyun G. Chiu, Jeffrey Sulpher(BC Cancer Agency)
Cited by 38
Related Papers
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)
|European Heart Journal|2022|2.7k
Baseline Cardiovascular Risk Assessment in Cancer Patients Scheduled to Receive Cardiotoxic Cancer Therapies: A Position Statement and New Risk Assessment Tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in Collaboration with the International Cardio-Oncology Society
|European Journal of Heart Failure|2020|767
Barriers and facilitators to implementing shared decision-making in clinical practice: a systematic review of health professionals' perceptions
|Implementation Science|2006|756
Predatory journals: no definition, no defence
|Nature|2019|723
Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement
|European Heart Journal|2021|589